Stocktoria
VYNE Therapeutics Inc. VYNE
VYNE Therapeutics Inc. (VYNE) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $570,000 at a -4646.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2081 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.283 |
| Retained earnings / assets | -0.707 |
| EBIT / assets | -0.296 |
| Equity / liabilities | -0.992 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VYNE | VYNE Therapeutics Inc. | 1/9 | -3.48 | — | — |
| SLN | Silence Therapeutics plc | 1/9 | -12.42 | — | -98.7% |
| ELAB | PMGC Holdings Inc. | 2/9 | — | — | — |
| VCNX | VACCINEX, INC. | 3/9 | — | — | — |
| QUCY | Quantum Cyber N.V. | 3/9 | — | — | — |
| MREO | Mereo BioPharma Group plc | 3/9 | — | — | — |
| BTAI | BioXcel Therapeutics, Inc. | 2/9 | — | — | — |
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
FAQ
Is VYNE financially healthy?
VYNE Therapeutics Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does VYNE pay a dividend?
No, VYNE Therapeutics Inc. does not currently pay a dividend.
How profitable is VYNE?
In FY2025, VYNE Therapeutics Inc. had a net margin of -4646.1%.
Is VYNE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VYNE Therapeutics Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.